Iatia makes an auspicious ASX debut
09 April, 2002 by Tanya HollisIt might not have been quite as exhilarating as his former life as a fighter pilot, but Iatia managing director Philippe Cussinet said the float of his company today was pretty exciting nonetheless.
Global patent tests would cut IP costs
05 April, 2002 by Tanya HollisPatent examinations should be standardised across the world to make appropriate intellectual property protection more affordable.
It's not just heaven that's missing an angel
05 April, 2002 by Melissa TrudingerThere is a major lack of angel investment in the biotech industry in Australia, according to investment groups such as Tinshed and Rothschild Bioscience.
Positive outlook for biotech in latest Deloittes index
05 April, 2002 by Iain ScottThe latest Deloitte index of companies on the Australian Stock Exchange's Healthcare and Biotechnology Index has painted a picture of increasing investor confidence in smaller stocks.
Biotech boosted at Invest Australia
04 April, 2002 by Daniella GoldbergFederal government agency Invest Australia's biotechnology team will quadruple in size after undergoing a major restructure to be completed July 1 this year.
Amrad's letter to shareholders: reject Circadian proposal
04 April, 2002 by Tanya HollisAmrad Corporation has issued a letter urging shareholders to reject a proposal to oust three of its directors.
Progen's distribution arm picks up new agencies
03 April, 2002 by Pete YoungBrisbane-based biotech Progen Industries has been appointed exclusive Australian distributor for two product ranges used by lab researchers.
Bristol-Myers warns high inventories to hit profit
02 April, 2002 by Deena BeasleyBristol-Myers Squibb, the top maker of cancer drugs, said on Monday that US wholesale inventories of its medicines are too high and reducing them will hurt future earnings.
We don't want a stoush over board: Amrad
28 March, 2002 by Tanya HollisAmrad Corporation's embattled board has urged major shareholder Circadian Technologies against holding a general meeting in May, calling instead for internal discussions.
Austin director joins Prima board
28 March, 2002 by Tanya HollisImmunologist Prof Mark Hogarth has been appointed to the board of Melbourne biotech Prima Biomed.
GroPep looks to sell off neuropathy research
28 March, 2002 by Tanya HollisGroPep is hoping to license out its research into a topical treatment for diabetic neuropathy after product development studies failed to come up with a suitable transdermal formulation.
Biologist takes up attorney role
28 March, 2002 by Tanya HollisA molecular geneticist has joined Freehills Carter Smith Beadle's biotechnology group as a patent attorney.
Autogen poised for Nasdaq listing
26 March, 2002 by Tanya HollisMelbourne gene discovery company Autogen has moved a step closer to listing on Nasdaq with the appointment of a strategic and corporate advisor in the United States.
The PM's advisers for science
25 March, 2002 by Pete YoungA consummate politician he may be, but John Howard is no scientist.
Inhalix rethinks after funding crunch
25 March, 2002 by Daniella GoldbergPromising medical device start-up company Inhalix has reassessed its strategy and has temporarily parked the company while it reviews its future options, according to CEO Graeme Woodrow.
